0001104659-19-051596.txt : 20190926 0001104659-19-051596.hdr.sgml : 20190926 20190926183009 ACCESSION NUMBER: 0001104659-19-051596 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190924 FILED AS OF DATE: 20190926 DATE AS OF CHANGE: 20190926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRICE MICHAEL DENNIS CENTRAL INDEX KEY: 0001247313 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17082 FILM NUMBER: 191119199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NOVELION THERAPEUTICS INC. CENTRAL INDEX KEY: 0000827809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 BUSINESS PHONE: (877) 764-3131 MAIL ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 FORMER COMPANY: FORMER CONFORMED NAME: QLT INC/BC DATE OF NAME CHANGE: 20000608 FORMER COMPANY: FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC DATE OF NAME CHANGE: 19960618 FORMER COMPANY: FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC DATE OF NAME CHANGE: 19941201 4 1 a4.xml 4 X0306 4 2019-09-24 0 0000827809 NOVELION THERAPEUTICS INC. NVLN 0001247313 PRICE MICHAEL DENNIS C/O NOVELION THERAPEUTICS INC. 1800-510 WEST GEORGIA STREET VANCOUVER A1 V6B 0M3 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Financial Officer Common Stock 2019-09-24 4 F 0 3926 0.76 D 14111 D The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. The vesting event occurred as the result of the acceleration of vesting on all outstanding equity awards under the Issuer's equity plans upon the closing of the previously announced transaction between, inter alia, the Issuer's operating subsidiary, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Amryt Pharma plc on September 24, 2019. As a result of the transaction, the Issuer was divested of Aegerion, which constituted a change of control or sale event under the Issuer's equity plans. /s/ Michael Price 2019-09-26